Tag: Hydroxyl-substituted pyrrolidinone racetam

Oxiracetam (ISF 2522, CGP 21690E) is a synthetic nootropic of the 2-pyrrolidinone (racetam) class, first synthesized in 1974 at the Istituto di Ricerche Farmacologiche (ISF) in Milan and introduced to the Italian market in 1984 under the trade name Neuromet for the treatment of cognitive disorders associated with primary degenerative dementia and multi-infarct dementia of mild to moderate degree. The compound is the 4-hydroxy analog of piracetam, the parent racetam; the hydroxyl substitution at position 4 of the pyrrolidinone ring produces a chiral center and confers approximately 2- to 5-fold greater potency than piracetam in standard rodent learning and memory paradigms and in in vitro assays of neurotransmitter release and synaptic potentiation. Oxiracetam is supplied and marketed as the racemic mixture of (R)- and (S)-enantiomers, though recent research has identified (S)-oxiracetam as the pharmacologically active enantiomer responsible for cognitive improvement in chronic cerebral hypoperfusion models.

The mechanism of action of oxiracetam is multimodal and incompletely characterized at the molecular level, consistent with the broader racetam class. The principal identified activities include positive allosteric modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, producing enhanced glutamatergic neurotransmission and facilitation of long-term potentiation in hippocampal circuits; stimulation of membrane-bound protein kinase C (PKC), particularly the alpha and gamma isoforms, with consequent phosphorylation of substrates involved in memory consolidation and synaptic plasticity; augmentation of hippocampal acetylcholine release through modulation of cholinergic interneuron excitability; and stimulation of phospholipid metabolism in neuronal membranes. Oxiracetam also increases the release of endogenous glutamate and D-aspartic acid from depolarized hippocampal slices, supporting a presynaptic facilitatory component of its mechanism. A 2020 study further demonstrated that oxiracetam attenuates amyloid-beta-induced microglial activation and reduces neuroinflammatory cytokine release (interleukin-1-beta, interleukin-6, and tumor necrosis factor alpha), adding an anti-inflammatory dimension to the pharmacological profile.

Pharmacokinetics in humans are characterized by oral bioavailability of 56 to 82 percent, peak plasma concentrations within 1 to 3 hours of dosing, and an elimination half-life of approximately 8 hours in healthy subjects. The compound is not appreciably metabolized; approximately 84 percent of an administered oral dose is recovered unchanged in urine within 24 hours, reflecting predominantly renal clearance. Brain penetration is modest, with central nervous system concentrations reaching approximately 5.3 percent of simultaneous blood levels. In patients with renal impairment, the elimination half-life extends to 10 to 68 hours, necessitating dose adjustment. The compound does not bind significantly to plasma proteins and does not undergo hepatic cytochrome P450 metabolism, resulting in a low drug-drug interaction potential.

The clinical evidence base spans multiple indications. In mild to moderate dementia of the Alzheimer type and multi-infarct dementia, multicenter randomized placebo-controlled trials conducted in Italy in the late 1980s and early 1990s demonstrated statistically significant improvements in cognitive function at 800 mg twice daily for 12 to 52 weeks, measured by the Mini Mental State Examination, memory batteries, and functional scales. A negative trial in Alzheimer’s disease (Green et al., 1992) and mixed results in traumatic brain injury temper the clinical profile. More recently, a 2025 multicenter phase 3 trial of the purified (S)-enantiomer (L-oxiracetam) in 590 patients with mild to moderate traumatic brain injury reported significantly greater cognitive improvement than both racemic oxiracetam and placebo at 90 days. A 2023 phase IV trial of racemic oxiracetam in post-stroke vascular cognitive impairment in South Korea did not support efficacy in preventing cognitive decline. The compound is approved as a prescription medicine in Italy, select European countries, Argentina, and China; it is not approved by the United States Food and Drug Administration.

This monograph reviews the chemistry, stereochemistry, and synthesis of oxiracetam; the multimodal molecular pharmacology including AMPA receptor modulation, PKC activation, neurotransmitter release augmentation, and anti-inflammatory activity; the comprehensive human pharmacokinetic record; the clinical evidence base across dementia, vascular cognitive impairment, traumatic brain injury, and neuroprotection indications; sourcing and quality verification considerations; reconstitution and handling; stack interactions; adverse-event signal; and a comparative assessment of five nootropic alternatives against oxiracetam on five competency standards.